Therapeutic Areas · Cardiometabolic Diseases
Cardiometabolic research increasingly relies on cardiovascular imaging, digital health, long-term outcomes and real-world evidence.
Overview
Cardiometabolic research increasingly relies on cardiovascular imaging, digital health, long-term outcomes and real-world evidence.
Guosa Life Sciences supports cardiometabolic programs with integrated technology-enabled operational capabilities.
Areas of Expertise
Specialized Capabilities
Why GLS
Our integrated enterprise combines scientific depth, operational excellence and collaborative partnerships to support development across diverse and demanding research environments.
The capability
We support cardiovascular, metabolic and renal programs: type 2 diabetes, obesity, dyslipidemia, heart failure, atherosclerotic disease and chronic kidney disease, including the large outcome studies these indications increasingly require.
Cardiometabolic development is characterized by long duration, large sample sizes and hard clinical endpoints. That combination makes retention, event capture and data completeness the operational priorities, because an outcome study that loses subjects to follow-up loses statistical power that no amount of enrollment recovers.
Regulatory considerations
Where the primary endpoint is a clinical event, independent adjudication is expected. A clinical events committee operating to a charter agreed in advance, blinded to treatment assignment, with defined source document requirements and a documented adjudication process, is the standard, and the charter needs to exist before the first potential event occurs rather than being drafted around it.
Cardiovascular safety expectations shape design in this area more than most. Programs are frequently required to demonstrate that a treatment does not carry unacceptable cardiovascular risk, which drives sample size, duration and the event capture apparatus. Long-term follow-up after treatment discontinuation is often required, and consent, retention and data collection have to be designed for it from the outset.
How an engagement runs
Endpoint definition, event capture strategy, adjudication charter and retention plan agreed before enrollment.
Clinical events committee constituted, source document requirements specified, and site training on event reporting.
Event ascertainment monitored, adjudication throughput tracked, retention managed against plan.
Adjudicated event analysis with documented handling of incomplete follow-up.
What you receive
An adjudication charter agreed before first event. Clinical events committee records. Retention and follow-up completeness reporting. Adjudicated endpoint datasets.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
Other Therapeutic Areas
Preventive and therapeutic vaccines, pandemic preparedness.
ExploreEarly-phase through global Phase III.
ExploreComplex endpoints and assessment.
ExploreMedical and aesthetic dermatology.
ExploreMedical and aesthetic dermatology.
ExploreAsthma, COPD and acute infection.
ExploreMaternal and reproductive health.
ExploreSmall, dispersed populations.
ExploreDevice and diagnostic studies.
ExplorePopulation and vaccination programs.
ExploreDiscuss your cardiometabolic diseases program with our multidisciplinary team.